The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
September 19th 2024
EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.
September 12th 2024
September 10th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Risk-Benefit of Coronary Calcium Scores May Preclude Inclusion from Traditional Risk Assessments
April 27th 2022A systematic review and meta-analysis suggest available evidence demonstrates the addition of coronary artery calcium scores provides incremental gain to traditional cardiovascular risk assessments but this benefit may not outweigh the risks and costs associated with CACS.
Initial eGFR Dips Common with SGLT2 Inhibitors, Not Typically Associated with Negative Outcomes
April 25th 2022An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.
Western US Resident, People of Color and Impoverished Increasingly Impacted by Poor Air Quality
April 21st 2022The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.
Cognitive Impairment Tied to Increased Cardiovascular Disease Risk in Type 2 Diabetes
April 21st 2022Analysis of the REWIND trial indicates cognitive impairment among patients with diabetes was associated with a 1.6 times greater risk of major adverse cardiovascular events and a 1.8 times greater risk of stroke or mortality.
Novel Drug Pivotal Trial Data Is Commonly Extrapolated for FDA Approval Indications
April 19th 2022About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.
Study Quantifies Life-Years Added from Meeting Treatment Goals in Type 2 Diabetes
April 18th 2022A microsimulation model provides insight into potential years of life expectancy gained by meeting recommended treatment goals for HbA1c, LDL-C, BMI, and blood pressure among adult patients with type 2 diabetes.
AHA Calls Attention to Growing Impact of NAFLD on Cardiovascular Disease Risk
April 14th 2022The latest scientific statement from the American Heart Association is aimed at improving the awareness of NAFLD and its associated cardiovascular risk among clinicians as well as optimizing diagnosis and early treatment strategies for patients with NAFLD.
ACC Guidance on CV Consequences of COVID-19, with Gregory Weiss, MD
April 12th 2022Dr. Gregory Weiss, a cardiovascular anesthesiologist, provides perspective into the American College of Cardiology's recently released guidance related to the long-term consequences of COVID-19, which includes information on myocarditis, return to athletics, and more.
Finerenone Provides Consistent Benefit for Reducing CV Risk, Regardless of CVD History
April 9th 2022A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.
Finerenone Reduces CV Risk in T2D and CKD, Regardless of ASCVD History
April 7th 2022A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.